Respiratory syncytial virus Prefusion F vaccine
Cell · 2023
DOI: 10.1016/j.cell.2023.05.048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2023. Verfasst von Ann R Falsey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Rochester, Rochester, NY, USA. Electronic address: ann_falsey@urmc.rochester.edu. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is the most common cause of serious respiratory infection in infants. Reinfections occur commonly, including in older adults. For six decades, effective vaccines remained elusive. Stabilization of the prefusion conformation of the RSV glycoprotein F was critical for development of effective vaccines to prevent RSV in older adults. To view this Bench to Bedside, open or download the PDF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Rochester, Rochester, NY, USA. Electronic address: ann_falsey@urmc.rochester.edu.
- Department of Medicine, University of Rochester, Rochester, NY, USA.
Zitieren
APA
Falsey, A. R., & Walsh, E. E. (2023). Respiratory syncytial virus Prefusion F vaccine. Cell. https://doi.org/10.1016/j.cell.2023.05.048
Vancouver
Falsey AR, Walsh EE. Respiratory syncytial virus Prefusion F vaccine. Cell. 2023. doi:10.1016/j.cell.2023.05.048
BibTeX
@article{Falsey2023,
author = {Falsey, Ann R and Walsh, Edward E},
title = {Respiratory syncytial virus Prefusion F vaccine},
journal = {Cell},
year = {2023},
doi = {10.1016/j.cell.2023.05.048}
}
EUVIMED